Side Effects of Semaglutide and Tirzepatide: What to Expect

Common Side Effects Comparison

Both semaglutide and tirzepatide belong to the GLP-1 receptor agonist class, and their side-effect profiles overlap considerably. The gastrointestinal tract is the primary area affected because these medications slow gastric emptying, reduce appetite signaling in the brain, and alter the speed at which food moves through the digestive system. Understanding what to expect at each stage of treatment helps patients prepare and reduces the likelihood of premature discontinuation.

Nausea is the single most reported side effect across clinical trials for both drugs. In the STEP trials evaluating semaglutide 2.4 mg, roughly 44 percent of participants experienced nausea at some point during treatment, compared to about 25 percent on placebo. The SURMOUNT trials for tirzepatide showed nausea rates ranging from 24 to 33 percent depending on the dose tier. Diarrhea, vomiting, constipation, and abdominal discomfort round out the top five complaints for both medications.

It is important to note that these percentages reflect the full course of treatment, and most patients who experience nausea find that it is concentrated in the early weeks or immediately after a dose increase. A meaningful number of patients report that nausea becomes mild or resolves entirely once they have been on a stable dose for several weeks. See semaglutide side effects and tirzepatide side effects for drug-specific breakdowns.

Why GI Side Effects Happen: The Mechanism

GLP-1 receptor agonists mimic a natural gut hormone called glucagon-like peptide-1. When you eat, your intestines release GLP-1, which signals the brain to reduce hunger, tells the pancreas to release insulin, and slows the rate at which food leaves your stomach. Semaglutide and tirzepatide amplify this process far beyond what the body does on its own, which is what makes them effective for weight loss but also what causes the gastrointestinal symptoms that many patients notice.

Delayed gastric emptying means food sits in the stomach longer than usual. This can produce a persistent feeling of fullness, bloating, and nausea, especially if a patient eats a large or high-fat meal. The brain's appetite centers are also being suppressed more strongly than normal, which can make even the thought of food unappealing during the adjustment period. For tirzepatide, the added GIP receptor activation provides an additional metabolic pathway that can affect gut motility in slightly different ways, though the net clinical experience is similar for most patients.

Understanding this mechanism is useful because it points directly to the most effective management strategies: eating smaller meals, avoiding heavy fats, staying hydrated, and following a gradual dose escalation schedule. Patients who understand the biology behind their symptoms tend to manage them more proactively and stick with treatment longer. Learn more about how tirzepatide works.

Managing GI Symptoms Effectively

Symptom management is one of the most important factors in treatment success. Studies consistently show that patients who receive upfront guidance about managing side effects are more likely to remain on therapy long enough to reach clinically meaningful weight loss. The following strategies are drawn from clinical guidelines and real-world patient experience.

For a deeper dive into practical meal strategies, see managing GI side effects and best foods while on tirzepatide.

Serious and Rare Side Effects

While the majority of side effects are gastrointestinal and self-limiting, both semaglutide and tirzepatide carry warnings for less common but more serious adverse events. Being aware of these does not mean they are likely, but knowing the warning signs allows patients to seek help promptly if needed.

Pancreatitis has been reported in a small number of patients taking GLP-1 medications. Symptoms include severe, persistent abdominal pain that may radiate to the back, often accompanied by nausea and vomiting that feel different from the typical GI discomfort associated with dose escalation. If you experience this type of pain, stop the medication and seek emergency care. The risk is slightly elevated in patients with a history of pancreatitis, heavy alcohol use, or very high triglycerides.

Gallbladder problems, including gallstones and cholecystitis, occur at higher rates during rapid weight loss regardless of the method. GLP-1 medications may add an independent risk factor by altering gallbladder motility. Symptoms include pain in the upper right abdomen, particularly after eating fatty foods, sometimes with fever or jaundice. Patients who lose weight rapidly should be monitored for gallbladder symptoms. Read more about tirzepatide pancreatitis warning signs.

Acute kidney injury has been reported, typically in the context of severe dehydration from prolonged vomiting or diarrhea. This underscores the importance of maintaining adequate fluid intake and seeking medical attention if vomiting prevents you from keeping liquids down for more than 24 hours. Patients with pre-existing kidney disease should have their renal function monitored more frequently during treatment.

Hair Loss, Fatigue, and Other Non-GI Effects

Beyond the gastrointestinal system, patients sometimes report side effects that are less well-known but can be distressing. Hair thinning, medically known as telogen effluvium, is one of the most discussed concerns in patient communities. This type of hair loss is triggered by rapid weight loss and significant caloric restriction rather than by the medication directly. When the body enters a large energy deficit, it prioritizes essential functions and may shift hair follicles into a resting phase, leading to increased shedding two to four months after the weight loss begins.

The good news is that telogen effluvium is almost always temporary. Hair growth typically resumes once weight stabilizes and nutritional intake normalizes. Patients can reduce the risk by ensuring adequate protein intake, typically 1.0 to 1.5 grams per kilogram of body weight per day, and by supplementing with biotin, iron, and zinc if blood levels are low. A slower rate of weight loss also helps, which is another reason to follow the recommended titration schedule rather than rushing to higher doses.

Fatigue and dizziness are reported by some patients, particularly during the early weeks of treatment. These symptoms often correlate with reduced caloric intake and mild dehydration rather than a direct pharmacological effect. Ensuring you eat enough to meet basic nutritional needs, even when appetite is suppressed, is essential. Some patients find that spacing their injection day away from important work or social commitments helps them manage transient fatigue. See our guide on the complete GLP-1 overview for broader context.

Semaglutide vs Tirzepatide: Which Is Better Tolerated?

This is one of the most common questions patients ask, and the honest answer is that there is no definitive winner. Head-to-head trial data is limited, and the existing evidence suggests that both medications have similar types of side effects with some variation in reported rates. Tirzepatide tends to show slightly lower nausea and vomiting percentages in clinical trials compared to semaglutide at equivalent dose levels, but it also has a wider dose range, and higher tirzepatide doses can produce GI symptoms comparable to semaglutide.

Individual variation matters more than trial averages. Some patients who struggle with nausea on semaglutide do better when switched to tirzepatide, and the reverse is also true. Factors like baseline GI health, concurrent medications, diet, stress levels, and even the speed of dose escalation can all influence tolerability. A patient with irritable bowel syndrome, for example, might find the constipation component of one medication more tolerable than the diarrhea profile of another.

The practical takeaway is that if one medication is not tolerable after a reasonable trial period with proper management strategies, switching to the other is a legitimate clinical option. Your provider can guide the timing and approach for a safe transition. For a full head-to-head breakdown, see tirzepatide vs semaglutide.

When to Seek Medical Help

Knowing when side effects cross the line from uncomfortable but normal to medically concerning is critical. Most GI symptoms during dose escalation are expected and manageable, but certain signs warrant immediate attention.

For a complete guide on recognizing warning signs, see when to call your doctor about GLP-1 side effects.

Long-Term Tolerability and What the Research Shows

One of the most reassuring findings from long-term trial extensions is that side effects generally improve with time. In the STEP extension studies for semaglutide, the majority of patients who experienced GI symptoms during the first 20 weeks reported significant improvement or complete resolution by week 68. Similar patterns have been observed in the SURMOUNT trials for tirzepatide, where early GI symptoms were the primary reason for dropout but became less of an issue for patients who persisted through the initial titration period.

Discontinuation rates due to side effects range from roughly 5 to 8 percent across the major clinical trials, meaning the vast majority of patients are able to continue treatment. For patients who do discontinue, the most common reason is nausea or vomiting that does not resolve despite management strategies. This is why proactive symptom management from the very beginning of treatment is so valuable, as it gives patients the best chance of reaching a stable maintenance dose where tolerability tends to be much better.

Long-term safety monitoring continues for both medications. Post-marketing surveillance studies are tracking outcomes in hundreds of thousands of patients to identify any rare adverse events that may not have appeared in the clinical trial populations. As of early 2026, no new major safety signals have emerged beyond what was identified in the original trials, though patients should stay engaged with their healthcare providers and report any unusual symptoms promptly. For broader context, explore which GLP-1 has the fewest side effects.

Sources

• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021.
• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022.
• FDA Prescribing Information: Wegovy (semaglutide) injection. Novo Nordisk. 2024.
• FDA Prescribing Information: Zepbound (tirzepatide) injection. Eli Lilly. 2024.
• Rubino DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8). JAMA. 2022.